On the Bleeding Edge: Mastering GI Emergencies and Inpatient GI Consultation (On-Demand) | 2026-Liver Pearls That Change Inpatient Management

Video Transcription

Video Summary

Pankaj Rajvanshi reviewed evidence-based liver-management decisions for hospitalized patients. Acute liver failure—coagulopathy and encephalopathy without prior liver disease developing within six months—requires urgent transplant evaluation. Acute-on-chronic liver failure involves organ failure and carries high mortality. N-acetylcysteine is appropriate for early non-acetaminophen acute liver failure and as an adjunct to prednisone for severe alcohol-associated hepatitis, but not as monotherapy.<br /><br />Refer patients with cirrhosis for transplant evaluation at MELD 12 or after their first decompensation, such as new ascites. Consider primary SBP prophylaxis for patients with ascitic protein below 1.5 plus advanced liver or renal dysfunction. Reserve albumin for SBP, large-volume paracentesis, and selected hepatorenal syndrome cases—not other infections or low serum albumin alone.<br /><br />Clinically significant portal hypertension can exist without varices. Nonselective beta blockers, particularly carvedilol, may reduce decompensation risk; noninvasive measures such as liver stiffness and platelet count can help identify candidates. Q&A addressed rifaximin access, encephalopathy management, steroid timing, and anticoagulation for portal vein thrombosis.

Asset Subtitle

Pankaj Rajanshi, MD

Keywords

acute liver failure

cirrhosis transplant referral

portal hypertension

N-acetylcysteine

albumin therapy

acute-on-chronic liver failure

transplant evaluation

nonselective beta blockers